Finance

Lists
Why is INBX down 2,15%?
Dive Deeper
INBX:NASDAQ
Inhibrx Biosciences Inc
US$97,93
-2,15%
(-2,15) 1D
US$97,93
0,00% (0,00)
After hours
Closed: 1 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INBX...
Open
US$100,71
High
US$102,16
Low
US$97,58
Mkt. cap
1,44 ຕື້
Avg. vol.
348,02 ພັນ
Volume
216,54 ພັນ
52-wk high
US$155,29
52-wk low
US$28,16
EPS
US$-8,88
Shares outstanding
14,72 ລ້ານ
No. of employees
110
Open
US$100,71
High
US$102,16
Low
US$97,58
Mkt. cap
1,44 ຕື້
Avg. vol.
348,02 ພັນ
Volume
216,54 ພັນ
52-wk high
US$155,29
52-wk low
US$28,16
EPS
US$-8,88
Shares outstanding
14,72 ລ້ານ
No. of employees
110
News stories
From web sources and news partners
About Inhibrx Biosciences Inc
CEO-
Employees110
Founded2024
HeadquartersLa Jolla, ແຄລິຟໍເນຍ, ສະຫະລັດ
SectorBiotechnology
Websiteinhibrx.com
Analyst ratings
Based on 3 analysts giving stock ratings to INBX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INBX in the last 3 months.
Highest
Current US$97,93
US$325,00 (+231,87%)
Average
US$266,67 (+172,31%)
Lowest
US$230,00 (+134,86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$245,00
+150,2%
09/09/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
US$230,00
+134,9%
09/08/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
US$325,00
+231,9%
08/21/2026
Unknown Analyst
Stifel Nicolaus
Buy
Initiated
US$150,00
+53,2%
04/08/2026
Last report
13 ສ.ຫ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$-2,34 / US$-1,34
-74,63%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
-
-
-
-
Cost of goods sold
28,54 ລ້ານ
25,35 ລ້ານ
25,22 ລ້ານ
23,90 ລ້ານ
Cost of revenue
28,54 ລ້ານ
25,35 ລ້ານ
25,22 ລ້ານ
23,90 ລ້ານ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,28 ລ້ານ
5,57 ລ້ານ
5,71 ລ້ານ
8,25 ລ້ານ
Operating expense
5,28 ລ້ານ
5,57 ລ້ານ
5,71 ລ້ານ
8,25 ລ້ານ
Total operating expenses
33,81 ລ້ານ
30,92 ລ້ານ
30,93 ລ້ານ
32,15 ລ້ານ
Operating income
-33,81 ລ້ານ
-30,92 ລ້ານ
-30,93 ລ້ານ
-32,15 ລ້ານ
Other non operating income
-46,00 ພັນ
-39,00 ພັນ
-12,00 ພັນ
-68,00 ພັນ
EBT including unusual items
-35,26 ລ້ານ
-32,83 ລ້ານ
-33,44 ລ້ານ
-36,65 ລ້ານ
EBT excluding unusual items
-35,26 ລ້ານ
-32,83 ລ້ານ
-33,44 ລ້ານ
-36,65 ລ້ານ
Income tax expense
-
-
-
3,00 ພັນ
Effective tax rate
-
-
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-35,26 ລ້ານ
-32,83 ລ້ານ
-33,44 ລ້ານ
-36,65 ລ້ານ
Net profit margin
-
-
-
-
Earnings per share
-2,28
-2,11
-2,15
-2,34
Interest and investment income
1,78 ລ້ານ
1,31 ລ້ານ
1,01 ລ້ານ
1,26 ລ້ານ
Interest expense
-3,18 ລ້ານ
-3,18 ລ້ານ
-3,51 ລ້ານ
-5,69 ລ້ານ
Net interest expenses
-1,40 ລ້ານ
-1,87 ລ້ານ
-2,50 ລ້ານ
-4,43 ລ້ານ
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,23 ລ້ານ
-30,36 ລ້ານ
-30,39 ລ້ານ
-31,63 ລ້ານ
Gain or loss from assets sale
3,00 ພັນ
9,00 ພັນ
-
14,00 ພັນ
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
ແອັບຂອງ Google